Skip to main content
Merck's non-Hodgkin lymphoma drug approved by FDA

Merck's Keytruda, or pembrolizumab, was approved by the FDA to treat pediatric and adult patients with refractory primary mediastinal large B-cell lymphoma who received two or more lines of therapy. The decision was backed by data from KEYNOTE-170 study, in which Keytruda treatment achieved a 45% response rate and a complete response rate of 11%.

Full Story: